CNS Drugs

, Volume 32, Issue 3, pp 259–267 | Cite as

Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the Evidence?

  • Isabelle Beuchat
  • Jan Novy
  • Andrea O. Rossetti
Review Article


Status epilepticus (SE) is one of the most frequent neurological emergencies. Despite this, understanding of its pathophysiology and evidence regarding its management is limited. Rapid, effective, and well-tolerated treatment to achieve seizure cessation is advocated to prevent brain damage or potentially lethal outcomes. The last two decades have witnessed an exponential increase in the number of available antiepileptic drugs (AEDs). These compounds, especially lacosamide and levetiracetam, in view of their intravenous formulation, have been increasingly prescribed in SE. These and other newer AEDs present a promising profile in terms of tolerability, with few centrally depressive effects, favorable pharmacokinetic properties, and fewer drug interactions than classical AEDs; conversely, they are more expensive. There is still no clear evidence to suggest a specific beneficial impact of newer AEDs on SE outcome, preventing any strong recommendation regarding their prescription in SE. Further comparative studies are urgently required to clarify their place and optimal use in the armamentarium of SE treatment.


Compliance with Ethical Standards


No sources of funding were used to prepare this manuscript.

Conflict of interest

I. Beuchat, J. Novy, and A.O. Rossetti have no conflicts of interest that are directly related to the content of this manuscript.


  1. 1.
    Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.CrossRefPubMedGoogle Scholar
  4. 4.
    Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand. 2017;135(1):92–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents. CNS Drugs. 2017;31(4):327–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav E&B. 2012;24(1):70–3.CrossRefGoogle Scholar
  8. 8.
    Rossetti AO. Are newer AEDs better than the classic ones in the treatment of status epilepticus? J Clin Neurophysiol. 2016;33(1):18–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Claassen J, Riviello JJ Jr, Silbergleit R. Emergency neurological life support: status epilepticus. Neurocrit Care. 2015;23(Suppl 2):S136–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr/Am Epilepsy Soc. 2016;16(1):48–61.CrossRefGoogle Scholar
  13. 13.
    Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure J Br Epilepsy Assoc. 2014;23(3):167–74.CrossRefGoogle Scholar
  14. 14.
    Misra UK, Kalita J. A comparison of four antiepileptic drugs in status epilepticus: experience from India. Int J Neurosci. 2016;126(11):1013–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2008;79(5):588–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol. 2005;54(1):34–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Ruegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy Behav E&B. 2008;12(3):477–80.CrossRefGoogle Scholar
  18. 18.
    Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47(7):1128–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28(5):734–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl 8):35–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord. 2009;2(2):79–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Gujjar AR, Nandhagopal R, Jacob PC, Al-Hashim A, Al-Amrani K, Ganguly SS, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study. Seizure. 2017;49:8–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam—pilot study. Epilepsy Res. 2015;114:52–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64(Pt A):110–5.Google Scholar
  27. 27.
    Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21(4):233–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav. 2009;15(4):467–9.CrossRefPubMedGoogle Scholar
  30. 30.
    De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13(1):57–78.CrossRefPubMedGoogle Scholar
  31. 31.
    Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15(1):47–55.CrossRefPubMedGoogle Scholar
  32. 32.
    Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54(9):901–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Cawello W, Stockis A, Andreas JO, Dimova S. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci. 2014;1329:18–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother. 2010;11(9):1595–602.CrossRefPubMedGoogle Scholar
  36. 36.
    Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag. 2009;5:757–66.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Brigo F, Trinka E. Randomized controlled trials in status epilepticus: Size matters. Epilepsia. 2017;58(5):915.CrossRefPubMedGoogle Scholar
  38. 38.
    Misra UK, Dubey D, Kalita J. A randomized controlled trial of lacosamide versus sodium valproate in status epilepticus. Epilepsia. 2017.Google Scholar
  39. 39.
    Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393–404.CrossRefPubMedGoogle Scholar
  40. 40.
    Strzelczyk A, Zollner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58(6):933–50.CrossRefPubMedGoogle Scholar
  41. 41.
    Kellinghaus C, Berning S, Stogbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129(5):294–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Sutter R, Marsch S, Ruegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs. 2013;27(4):321–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Belcastro V, Vidale S, Pierguidi L, Sironi L, Tancredi L, Striano P, et al. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: a proof-of-concept, observational study. Seizure. 2013;22(10):905–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Miro J, Toledo M, Santamarina E, Ricciardi AC, Villanueva V, Pato A, et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure J Br Epilepsy Assoc. 2013;22(1):77–9.CrossRefGoogle Scholar
  45. 45.
    Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Santamarina E, Toledo M, Sueiras M, Raspall M, Ailouti N, Lainez E, et al. Usefulness of intravenous lacosamide in status epilepticus. J Neurol. 2013;260(12):3122–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Garces M, Villanueva V, Mauri JA, Suller A, Garcia C, Lopez Gonzalez FJ, et al. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav. 2014;36:144–52.CrossRefPubMedGoogle Scholar
  48. 48.
    Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148–52.CrossRefPubMedGoogle Scholar
  49. 49.
    Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14(3):348–53.CrossRefPubMedGoogle Scholar
  50. 50.
    Legros B, Depondt C, Levy-Nogueira M, Ligot N, Mavroudakis N, Naeije G, et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care. 2014;20(3):484–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Perrenoud M, Andre P, Alvarez V, Stahli C, Decosterd LA, Rossetti AO, et al. Intravenous lacosamide in status epilepticus: correlation between loading dose, serum levels, and clinical response. Epilepsy Res. 2017;135:38–42.CrossRefPubMedGoogle Scholar
  52. 52.
    Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.CrossRefPubMedGoogle Scholar
  53. 53.
    Niquet J, Suchomelova L, Thompson K, Klitgaard H, Matagne A, Wasterlain C. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia. 2017;58(7):1199–207.CrossRefPubMedGoogle Scholar
  54. 54.
    Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia. 2011;52(Suppl 8):70–1.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70(Pt A):177–81.Google Scholar
  56. 56.
    Kalss GRA, Leitinger M, Georg P, Novak H, Neuray C, Kreidenhuber R, Höfler J, Kuchukhidze G, Trinka E. Intravenous Brivaracetam in Status epilepticus—a retrospectie single centre study. Epilepsia. 2018 (in press). Google Scholar
  57. 57.
    Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61–5.CrossRefPubMedGoogle Scholar
  59. 59.
    Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4(6):757–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Hottinger A, Sutter R, Marsch S, Ruegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26(9):761–72.CrossRefPubMedGoogle Scholar
  61. 61.
    Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand. 2012;125(2):e7–11.CrossRefPubMedGoogle Scholar
  62. 62.
    Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98(2–3):232–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60(2):332–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Madzar D, Kuramatsu JB, Gerner ST, Huttner HB. Assessing the value of topiramate in refractory status epilepticus. Seizure. 2016;38:7–10.CrossRefPubMedGoogle Scholar
  65. 65.
    Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010;51(10):2207–10.CrossRefPubMedGoogle Scholar
  66. 66.
    Swisher CB, Doreswamy M, Husain AM. Use of pregabalin for nonconvulsive seizures and nonconvulsive status epilepticus. Seizure. 2013;22(2):116–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246–56.CrossRefPubMedGoogle Scholar
  68. 68.
    Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724–33.CrossRefPubMedGoogle Scholar
  69. 69.
    Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.CrossRefPubMedGoogle Scholar
  70. 70.
    Redecker J, Wittstock M, Benecke R, Rosche J. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav. 2015;45:176–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I, et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav. 2015;49:354–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Rosche J, Kampf C, Benecke R. Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belg. 2014;114(3):243–4.CrossRefPubMedGoogle Scholar
  73. 73.
    Santamarina E, Sueiras M, Lidon RM, Guzman L, Baneras J, Gonzalez M, et al. Use of perampanel in one case of super-refractory hypoxic myoclonic status: Case report. Epilepsy Behav Case Rep. 2015;4:56–9.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Steinhoff BJ, Bacher M, Kurth C, Staack AM, Kornmeier R. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep. 2016;6:28–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82(8):665–70.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132(6):435–9.CrossRefPubMedGoogle Scholar
  77. 77.
  78. 78.
    Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82(3):342–52.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Erstad BL, Patanwala AE. Ketamine for analgosedation in critically ill patients. J Crit Care. 2016;35:145–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–503.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Litt B, Wityk RJ, Hertz SH, Mullen PD, Weiss H, Ryan DD, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia. 1998;39(11):1194–202.CrossRefPubMedGoogle Scholar
  82. 82.
    Marchi NA, Novy J, Faouzi M, Stahli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656–64.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344–9.CrossRefPubMedGoogle Scholar
  85. 85.
    Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260(2):421–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27–34.CrossRefPubMedGoogle Scholar
  87. 87.
    Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77(5):611–5.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89–92.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Isabelle Beuchat
    • 1
  • Jan Novy
    • 1
  • Andrea O. Rossetti
    • 1
  1. 1.Department of Clinical Neurosciences, Service de Neurologie, Centre Hospitalier Universitaire Vaudois (CHUV), CHUV-BH07University of LausanneLausanneSwitzerland

Personalised recommendations